Associated Papers
Impact of KRAS-G12 Mutations on the KRAS-GTP Bound Conformational Dynamics: Structure, Free Energy Barriers and Drugging Pockets.
Hu Z et al.
Jacs Au, 2026
Sustained Response to Anti-PD-1 Therapy in Combination with Nab-Paclitaxel in Metastatic Testicular Germ Cell Tumor Harboring the KRAS-G12V Mutation: A Case Report.
Pan J et al.
Urologia Internationalis, 2025
Insight into structural dynamics involved in activation mechanism of full length KRAS wild type and P-loop mutants.
Jani V et al.
Heliyon, 2024
Single-cell signaling analysis reveals that Major Vault Protein facilitates RasG12C inhibitor resistance.
Zhang JZ et al.
Biorxiv : the Preprint Server for Biology, 2023
37873412 (PubMed )
Supplement: NIHPP2023.10.02.560617v1-supplement-1.pdf
Covalent fragment mapping of KRasG12C revealed novel chemotypes with in vivo potency.
Orgován Z et al.
European Journal of Medicinal Chemistry, 2023
The prevalence and real-world therapeutic analysis of Chinese patients with KRAS-Mutant Non-Small Cell lung cancer.
Chen H et al.
Cancer Medicine, 2022
Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer.
Judd J et al.
Molecular Cancer Therapeutics, 2021
Frequency of KRAS p.Gly12Cys Mutation in Brazilian Patients With Lung Cancer.
Cavagna R et al.
Jco Global Oncology, 2021
Generation of KS-58 as the first K-Ras(G12D)-inhibitory peptide presenting anti-cancer activity in vivo.
Sakamoto K et al.
Scientific Reports, 2020
A Real-World Study in Advanced Non-Small Cell Lung Cancer with KRAS Mutations.
Lei L et al.
Translational Oncology, 2020
[Allele-specific inhibitors of mutant KRAS are in the focus of RASopathy consortium].
Nyíri K et al.
Magyar Onkologia, 2019
Expression profiling and microRNA regulation of the LKB1 pathway in young and aged lung adenocarcinoma patients.
Boldrini L et al.
Biomedical Reports, 2018
Select a paper to view details